Effect of HER-2 negative on the recurrence and survival of patients with type Luminal breast cancer

Abstract

Objective To investigate the effect of HER-2 negative on the recurrence and survival of patients with type luminal breast cancer. Methods One hundred and sixty-two patients with HER-2 negative type luminal breast cancer were selected from January 2008 to January 2011, according to DFS, 116 patients with recurrence within 5 years were included in the recent recurrence group, 46 patients with recurrence above 5 years were included in the long-term recurrence group. All of them were followed up until May 31th, 2016. The influencing factors of the recurrence time, clinical pathological characteristics, the location of the first recurrence and metastasis and survival difference were observed. Results The median disease-free-survival (DFS) of patients with lymph nodes metastasis was more than 4, vascular tumor thrombus and lower levels of endocrine therapy, adjuvant radiotherapy was evidently lower than other patients, the differences were significant (P<0.05). In multivariate analysis, the number of lymph node metastases, the degree of endocrine therapy, and whether the adjuvant therapy were evidently associated with recurrence in patients(P<0.05). In recent recurrence group, there was a high proportion of patients with four or more lymph node transfer number, with vascular tumor thrombus, negative ER, the single positive hormone receptor, endocrine treatment standard; In the long-term recurrence group, the proportion of patients with double positive hormone receptor was higher, the difference was significant(P<0.05). The proportion of lung metastasis, ratio of visceral metastasis, multiple organ metastasis in the long-term recurrence group were evidently higher than those in the recent recurrence group, the differences were significant (P<0.05). The median OS in the long-term recurrence group was higher than that in the recent recurrence group(P<0.05). Conclusions The significant independent factors associated with DFS in patients with HER-2 negative type Luminal breast cancer were the number of lymph node metastases, the degree of endocrine therapy, and whether they were treated by adjuvant radiotherapy. There is obvious difference in clinical pathological characteristics and the location of the first recurrence and metastasis between recent recurrence group and long-term recurrence group, the survival status of the long-term recurrence group is better than that of the recent recurrence group. Key words: HER-2 negative type Luminal breast cancer; Short term recurrence; Long term recurrence; Survival condition